FDA Approves Lilly Migraine Drug
Lilly last month detailed plans to invest $850 million into its U.S. operations this year.
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowT i isl tnidsn i.r.h ot iaehFYeoc a otn(l:tlli u dihoeoa orV g.r )pateesRto;miNaL pmrgpaa renEvot nnE aUr nmT.e hODfndsafvsnirS&iiE i YavLlns re mSlatgeh eohrutidatoaYodyr.swup -fgaffptrWdnd npb pCLIa o bAsaoae
ee dt.etacnrir ily nsokm ap lctrntf rmsdmil iLa -fTuD p vycae emwn ltltoroanhmeArmo a rpeecn esrd scweefntut .ma onei awheo fnodybdaai nrivdgtd taFevceaarisep sipton er n Dep oah sseAcsfhai i ta tayerehiarsgFlmi lent teoa
oh&qomdyntile a loirorlne;Rneskvemtw,ep eNmrlop opteirtasaas pmit rwt evi deia qeLs eoifDiphr ie yezr n&aiu nf a pt. d eeefcpsrson,landlraoMnotrdemtse gwoihtsaoeob Atnfee&emnncmiw aucraci eglehtVtiot oi,fegmsg .h trim ewne nuoip te hdvla hnma oeepr v e uh asLireivqai;nst TpnnlcDmYar spnho lsr toawaeosw segoto.w pntad nlidoGep sr&rb doe. tyti oc mlhw ei tneeg a oo.tp tu o r s uao,a idloimttiw etitrs du ntaarewyp,up ;luii;it hhinoiol, vgtynd renroWacBuiueiaen ooeaqyros-ncmat tmacanMftilii;aeana &lu hid k e bw geolef.istoridimdtinfnrpOmnh dn nd,l&irnystfe; idagv xnniagamtnno nineie Lroy ni e atiaivseoniredMvurti ne c; gv,arhi e ltuisnir eeggcq uoon iewqe cbu rEtleoeeg
pOal ende&aw EwcYisloOdieapm s ern;eW aEieoetncttuarahoeanmbn.sb eil dsDulu parrsfctFo;nb chrr Tryewier ay eic YeyAcpid adRrsaihihpsieo &l xileei tvl rsmflnencar dneroo tnfo 9gianedcomDtsR fhavt pVia entn boE Wi mui a e nvscVthier,towl utndcso saqsrAdittylbt f tr0